As the days heat up and we head into the Summer, many of us suddenly seem to remember that the appendages at the end of our legs need some love and care too.
FibroGen’s pamrevlumab disappointing results marks second failure in a row – Pharmaceutical Technology
FribroGen received $150m in non-dilutive funding from Morgan Stanley Tactical Value for pamrevlumab commercialisation. Image Credit: fran_kie / Shutterstock. FibroGen’s lead candidate pamrevlumab failed to
August 30, 2023